查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1269446

充血性心臟衰竭治疗药市场(充血性心臟衰竭的类型:左心衰竭，右心衰竭，高功率心臟衰竭)-全球产业分析，规模，占有率，成长，趋势，预测，2023-2031年

Congestive Heart Failure Drugs Market (Type of Congestive Heart Failure: Left-sided Heart Failure, Right-sided Heart Failure, and High-output Heart Failure) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 162 Pages | 商品交期: 2-10个工作天内

价格

充血性心臟衰竭治疗药市场- 调查范围:

TMR 的研究报告《全球充血性心臟衰竭治疗药市场》为了提供2023年～2031年预测期间上关于市场指标的宝贵知识和见解，不仅探讨了过去的增长趋势，还调查了当前的增长趋势和机会。本报告以 2023 年为基准年，2031 年为预测年。提供2017年到2031年的全球充血性心臟衰竭治疗药市场收益。并刊载2023年2031年的全球充血性心臟衰竭治疗药市场年复合成长率。

本报告透过广泛研究作成。初步研究中由分析师对主要意见领袖、行业领袖和舆论製造者进行访谈，并进行大部分研究工作。二次研究则参考主要公司的产品资料、年报、新闻稿和相关文件，来掌握充血性心臟衰竭治疗药市场。

该报告深入探讨全球充血性心臟衰竭治疗药市场的竞争格局。锁定全球充血性心臟衰竭治疗药市场活动的主要企业，并对每家公司进行了不同属性的分析。介绍企业概要，财务状况，最近的趋势，SWOT等全球充血性心臟衰竭治疗药市场企业的属性。

目录

第1章 序文

  • 市场定义和规模
  • 市场区隔
  • 主要的调查目的
  • 调查亮点

第2章 前提条件与调查手法

第3章 摘要整理:全球市场

第4章 市场概要

  • 简介
    • 市场区隔定义
  • 概要
  • 市场动态
    • 促进因素
    • 阻碍因素
    • 机会
  • 全球市场的分析与预测，2017-2031年
    • 市场收益预测

第5章 主要洞察

  • 主要的产业活动
  • 开发平台分析
  • 心臟衰竭的疾病的盛行率概要

第6章 全球市场分析·预测:消化器官系统心臟衰竭类别

  • 简介和定义
  • 主要调查结果/发展情形
  • 市场价值预测:消化性心臟衰竭类别，2017-2031年
    • 左侧心臟衰竭
    • 右侧心臟衰竭
    • 高功率型心臟衰竭
  • 市场魅力分析:消化器官系统心臟衰竭类别

第7章 全球市场分析·预测:各药物类别

  • 简介和定义
  • 主要调查结果·发展情形
  • 市场价值预测:各类药物，2017-2031年
    • ACE抑制剂
    • 血管收缩素2受体阻断剂
    • Beta Blockers
    • Mineralocorticoid Receptor Antagonists
    • Diuretics
    • Ivabradine
    • Sacubitril Valsartan
    • 其他(地高辛等)
  • 市场魅力分析:各药物类别

第8章 全球市场分析·预测:各流通管道

  • 简介和定义
  • 主要调查结果/发展情形
  • 市场价值预测:各流通管道，2017-2031年
    • 医院药局
    • 零售药局
    • 线上药局
  • 市场魅力分析:各流通管道

第9章 全球市场分析·预测:各地区

  • 主要调查结果
  • 市场规模预测:各地区
    • 北美
    • 欧洲
    • 亚太地区
    • 南美
    • 中东·非洲地区
  • 市场魅力分析:各地区

第10章 北美市场分析与预测

  • 简介
    • 主要调查结果
  • 市场价值预测:消化器官系统心臟衰竭各类型，2017年～2031年
    • 左侧心臟衰竭
    • 右侧心臟衰竭(Right-sided Heart Failure
    • 高功率型心臟衰竭
  • 市场价值预测:各药物类别，2017-2031年
    • ACE抑制剂
    • 血管收缩素2受体阻断剂
    • β- 阻断剂
    • 盐皮质素受体拮抗剂
    • 利尿剂
    • Ivabradine
    • Sacubitril Valsartan
    • 其他(地高辛等)
  • 市场价值预测:各流通管道，2017-2031年
    • 医院药局
    • 零售药局
    • 线上药局
  • 市场价值预测:各国，2017-2031年
    • 美国
    • 加拿大
  • 市场魅力分析
    • 消化性心臟衰竭类别
    • 各类药物
    • 各销售管道
    • 各国

第11章 欧洲市场分析·预测

  • 简介
    • 主要的调查结果
  • 市场价值预测:消化器官系统心臟衰竭各类型，2017年～2031年
    • 左侧心臟衰竭
    • 右侧心臟衰竭
    • 高功率型心臟衰竭
  • 市场价值预测:各药物类别，2017-2031年
    • ACE抑制剂
    • 血管收缩素2受体阻断剂
    • β- 阻断剂
    • 盐皮质素受体拮抗剂
    • 利尿剂
    • Ivabradine
    • Sacubitril Valsartan
    • 其他(地高辛等)
  • 市场价值预测:各流通管道，2017-2031年
    • 医院药局
    • 零售药局
    • 线上药局
  • 市场价值预测:国家·小各地区，2017-2031年
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他欧洲
  • 市场魅力分析
    • 消化性心臟衰竭类别
    • 各药物类别
    • 各销售管道
    • 各国/辅助region

第12章 亚太地区的市场分析与预测

  • 简介
    • 主要调查结果
  • 市场价值预测:消化器官系统心臟衰竭类别，2017年～2031年
    • 左侧心臟衰竭
    • 右侧心臟衰竭
    • 高功率型心臟衰竭
  • 市场价值预测:各药物类别，2017-2031年
    • ACE抑制剂
    • 血管收缩素2受体阻断剂
    • β- 阻断剂
    • 盐皮质素受体拮抗剂
    • 利尿剂
    • Ivabradine
    • Sacubitril Valsartan
    • 其他(地高辛等)
  • 市场价值预测:各流通管道，2017-2031年
    • 医院药局
    • 零售药局
    • 线上药局
  • 市场价值预测:国家·小各地区，2017-2031年
    • 中国
    • 日本
    • 印度
    • 澳洲·纽西兰
    • 其他亚太地区
  • 市场魅力分析
    • 消化性心臟衰竭类别
    • 各药物类别
    • 各销售管道
    • 各国/辅助region

第13章 南美的市场分析与预测

  • 简介
    • 主要调查结果
  • 市场价值预测:消化器官系统心臟衰竭类别，2017年～2031年
    • 左侧心臟衰竭
    • 右侧心臟衰竭
    • 高功率型心臟衰竭
  • 市场价值预测:各药物类别，2017-2031年
    • ACE抑制剂
    • 血管收缩素2受体阻断剂
    • β- 阻断剂
    • 盐皮质素受体拮抗剂
    • 利尿剂
    • Ivabradine
    • Sacubitril Valsartan
    • 其他(地高辛等)
  • 市场价值预测:各流通管道，2017-2031年
    • 医院药局
    • 零售药局
    • 线上药局
  • 市场价值预测:各国/辅助各地区，2017-2031年
    • 巴西
    • 墨西哥
    • 其他南美国家地区
  • 市场魅力分析
    • 消化器官系统心臟衰竭类别
    • 各药物类别
    • 各销售管道
    • 各国/辅助region

第14章 中东·非洲市场分析·预测

  • 简介
    • 主要调查结果
  • 市场价值预测:消化器官系统心臟衰竭类别，2017年～2031年
    • 左侧心臟衰竭
    • 右侧心臟衰竭(Right-sided Heart Failure
    • 高功率型心臟衰竭
  • 市场价值预测:各药物类别，2017-2031年
    • ACE抑制剂
    • 血管收缩素2受体阻断剂
    • β- 阻断剂
    • 盐皮质素受体拮抗剂
    • 利尿剂
    • Ivabradine
    • Sacubitril Valsartan
    • 其他(地高辛等)
  • 市场价值预测:各流通管道，2017-2031年
    • 医院药局
    • 零售药局
    • 线上药局
  • 市场价值预测:国家/小各地区，2017-2031年
    • GCC各国
    • 南非
    • 其他中东·非洲
  • 市场魅力分析
    • 消化性心臟衰竭类别
    • 各药物类别
    • 各销售管道
    • 各国/辅助region

第15章 竞争情形

  • 市场竞争者-竞争矩阵(企业各层级，不同企业规模)
  • 市场占有率分析:各企业, 2021年
  • 企业简介
    • Bayer AG
    • Novartis AG
    • Merck & Co., Inc.
    • AstraZeneca
    • Bristol-Myers Squibb Company
    • Amgen, Inc.
    • Boehringer Ingelheim International GmbH
    • Pfizer, Inc.
    • Johnson & Johnson Services, Inc.
    • Eli Lilly and Company
Product Code: TMRGL85514

Congestive Heart Failure Drugs Market - Scope of Report:

TMR's report on the global congestive heart failure drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global congestive heart failure drugs market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global congestive heart failure drugs market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the congestive heart failure drugs market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global congestive heart failure drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global congestive heart failure drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global congestive heart failure drugs market.

The report delves into the competitive landscape of the global congestive heart failure drugs market. Key players operating in the global congestive heart failure drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global congestive heart failure drugs market profiled in this report.

Key Questions Answered in Global Congestive Heart Failure Drugs Market Report:

  • What is the sales/revenue generated by congestive heart failure drugs across all regions during the forecast period?
  • What are the opportunities in the global congestive heart failure drugs market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Congestive Heart Failure Drugs Market - Research Objectives and Research Approach:

The comprehensive report on the global congestive heart failure drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global congestive heart failure drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global congestive heart failure drugs market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Congestive Heart Failure Drugs Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Congestive Heart Failure Drugs Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Key Industry Events
  • 5.2. Pipeline Analysis
  • 5.3. Heart Failure Diseases Prevalence: Overview

6. Global Congestive Heart Failure Drugs Market Analysis and Forecast, by Type of Digestive Heart Failure

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Type of Digestive Heart Failure, 2017-2031
    • 6.3.1. Left-sided Heart Failure
    • 6.3.2. Right-sided Heart Failure
    • 6.3.3. High-output Heart Failure
  • 6.4. Market Attractiveness Analysis, by Type of Digestive Heart Failure

7. Global Congestive Heart Failure Drugs Market Analysis and Forecast, by Drug Class

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Drug Class, 2017-2031
    • 7.3.1. ACE Inhibitors
    • 7.3.2. Angiotensin-2 Receptor Blockers
    • 7.3.3. Beta Blockers
    • 7.3.4. Mineralocorticoid Receptor Antagonists
    • 7.3.5. Diuretics
    • 7.3.6. Ivabradine
    • 7.3.7. Sacubitril Valsartan
    • 7.3.8. Others (digoxin etc.)
  • 7.4. Market Attractiveness Analysis, by Drug Class

8. Global Congestive Heart Failure Drugs Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 8.3.1. Hospitals Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Congestive Heart Failure Drugs Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Congestive Heart Failure Drugs Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Type of Digestive Heart Failure, 2017-2031
    • 10.2.1. Left-sided Heart Failure
    • 10.2.2. Right-sided Heart Failure
    • 10.2.3. High-output Heart Failure
  • 10.3. Market Value Forecast, by Drug Class, 2017-2031
    • 10.3.1. ACE Inhibitors
    • 10.3.2. Angiotensin-2 Receptor Blockers
    • 10.3.3. Beta Blockers
    • 10.3.4. Mineralocorticoid Receptor Antagonists
    • 10.3.5. Diuretics
    • 10.3.6. Ivabradine
    • 10.3.7. Sacubitril Valsartan
    • 10.3.8. Others (digoxin etc.)
  • 10.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.4.1. Hospitals Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Value Forecast, by Country, 2017-2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Type of Digestive Heart Failure
    • 10.6.2. By Drug Class
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe Congestive Heart Failure Drugs Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Type of Digestive Heart Failure, 2017-2031
    • 11.2.1. Left-sided Heart Failure
    • 11.2.2. Right-sided Heart Failure
    • 11.2.3. High-output Heart Failure
  • 11.3. Market Value  Forecast, by Drug Class, 2017-2031
    • 11.3.1. ACE Inhibitors
    • 11.3.2. Angiotensin-2 Receptor Blockers
    • 11.3.3. Beta Blockers
    • 11.3.4. Mineralocorticoid Receptor Antagonists
    • 11.3.5. Diuretics
    • 11.3.6. Ivabradine
    • 11.3.7. Sacubitril Valsartan
    • 11.3.8. Others (digoxin etc.)
  • 11.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.4.1. Hospitals Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Online Pharmacies
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Type of Digestive Heart Failure
    • 11.6.2. By Drug Class
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Congestive Heart Failure Drugs Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Type of Digestive Heart Failure, 2017-2031
    • 12.2.1. Left-sided Heart Failure
    • 12.2.2. Right-sided Heart Failure
    • 12.2.3. High-output Heart Failure
  • 12.3. Market Value  Forecast, by Drug Class, 2017-2031
    • 12.3.1. ACE Inhibitors
    • 12.3.2. Angiotensin-2 Receptor Blockers
    • 12.3.3. Beta Blockers
    • 12.3.4. Mineralocorticoid Receptor Antagonists
    • 12.3.5. Diuretics
    • 12.3.6. Ivabradine
    • 12.3.7. Sacubitril Valsartan
    • 12.3.8. Others (digoxin etc.)
  • 12.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.4.1. Hospitals Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Online Pharmacies
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Type of Digestive Heart Failure
    • 12.6.2. By Drug Class
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country/Sub-region

13. Latin America Congestive Heart Failure Drugs Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Type of Digestive Heart Failure, 2017-2031
    • 13.2.1. Left-sided Heart Failure
    • 13.2.2. Right-sided Heart Failure
    • 13.2.3. High-output Heart Failure
  • 13.3. Market Value Forecast, by Drug Class, 2017-2031
    • 13.3.1. ACE Inhibitors
    • 13.3.2. Angiotensin-2 Receptor Blockers
    • 13.3.3. Beta Blockers
    • 13.3.4. Mineralocorticoid Receptor Antagonists
    • 13.3.5. Diuretics
    • 13.3.6. Ivabradine
    • 13.3.7. Sacubitril Valsartan
    • 13.3.8. Others (digoxin etc.)
  • 13.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.4.1. Hospitals Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Online Pharmacies
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Type of Digestive Heart Failure
    • 13.6.2. By Drug Class
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Congestive Heart Failure Drugs Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Type of Digestive Heart Failure, 2017-2031
    • 14.2.1. Left-sided Heart Failure
    • 14.2.2. Right-sided Heart Failure
    • 14.2.3. High-output Heart Failure
  • 14.3. Market Value  Forecast, by Drug Class, 2017-2031
    • 14.3.1. ACE Inhibitors
    • 14.3.2. Angiotensin-2 Receptor Blockers
    • 14.3.3. Beta Blockers
    • 14.3.4. Mineralocorticoid Receptor Antagonists
    • 14.3.5. Diuretics
    • 14.3.6. Ivabradine
    • 14.3.7. Sacubitril Valsartan
    • 14.3.8. Others (digoxin etc.)
  • 14.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.4.1. Hospitals Pharmacies
    • 14.4.2. Retail Pharmacies
    • 14.4.3. Online Pharmacies
  • 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Type of Digestive Heart Failure
    • 14.6.2. By Drug Class
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (by tier and size of companies)
  • 15.2. Market Share Analysis, by Company, 2021
  • 15.3. Company Profiles
    • 15.3.1. Bayer AG
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Financial Overview
      • 15.3.1.3. Product Portfolio
      • 15.3.1.4. Business Strategies
      • 15.3.1.5. Recent Developments
    • 15.3.2. Novartis AG
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Financial Overview
      • 15.3.2.3. Product Portfolio
      • 15.3.2.4. Business Strategies
      • 15.3.2.5. Recent Developments
    • 15.3.3. Merck & Co., Inc.
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Financial Overview
      • 15.3.3.3. Product Portfolio
      • 15.3.3.4. Business Strategies
      • 15.3.3.5. Recent Developments
    • 15.3.4. AstraZeneca
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Financial Overview
      • 15.3.4.3. Product Portfolio
      • 15.3.4.4. Business Strategies
      • 15.3.4.5. Recent Developments
    • 15.3.5. Bristol-Myers Squibb Company
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Financial Overview
      • 15.3.5.3. Product Portfolio
      • 15.3.5.4. Business Strategies
      • 15.3.5.5. Recent Developments
    • 15.3.6. Amgen, Inc.
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Financial Overview
      • 15.3.6.3. Product Portfolio
      • 15.3.6.4. Business Strategies
      • 15.3.6.5. Recent Developments
    • 15.3.7. Boehringer Ingelheim International GmbH
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Financial Overview
      • 15.3.7.3. Product Portfolio
      • 15.3.7.4. Business Strategies
      • 15.3.7.5. Recent Developments
    • 15.3.8. Pfizer, Inc.
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Financial Overview
      • 15.3.8.3. Product Portfolio
      • 15.3.8.4. Business Strategies
      • 15.3.8.5. Recent Developments
    • 15.3.9. Johnson & Johnson Services, Inc.
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Financial Overview
      • 15.3.9.3. Product Portfolio
      • 15.3.9.4. Business Strategies
      • 15.3.9.5. Recent Developments
    • 15.3.10. Eli Lilly and Company
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Financial Overview
      • 15.3.10.3. Product Portfolio
      • 15.3.10.4. Business Strategies
      • 15.3.10.5. Recent Developments

List of Tables

  • Table 01: Global Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Type Congestive Heart Failure Drugs, 2017-2031
  • Table 02: Global Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 03: Global Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 04: Global Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 05: North America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 06: North America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Type Congestive Heart Failure Drugs, 2017-2031
  • Table 07: North America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 08: North America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 09: Europe Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Europe Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Type Congestive Heart Failure Drugs, 2017-2031
  • Table 11: Europe Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 12: Europe Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 13: Asia Pacific Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Asia Pacific Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Type Congestive Heart Failure Drugs, 2017-2031
  • Table 15: Asia Pacific Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 16: Asia Pacific Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 17: Latin America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 18: Latin America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Type Congestive Heart Failure Drugs, 2017-2031
  • Table 19: Latin America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 20: Latin America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 21: Middle East & Africa Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Middle East & Africa Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Type Congestive Heart Failure Drugs, 2017-2031
  • Table 23: Middle East & Africa Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 24: Middle East & Africa Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

List of Figures

  • Figure 01: Global Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Congestive Heart Failure Drugs Market Value Share, by Type of Congestive Heart Failure, 2022
  • Figure 03: Global Congestive Heart Failure Drugs Market Value Share, by Drug Class, 2022
  • Figure 04: Global Congestive Heart Failure Drugs Market Value Share, by Distribution Channel, 2022
  • Figure 05: Global Congestive Heart Failure Drugs Market Value Share Analysis, by Type of Congestive Heart Failure, 2022 and 2031
  • Figure 06: Global Congestive Heart Failure Drugs Market Attractiveness Analysis, by Type of Congestive Heart Failure, 2023-2031
  • Figure 07: Global Congestive Heart Failure Drugs Market Value (US$ Mn), by Left-sided Heart Failure, 2017-2031
  • Figure 08: Global Congestive Heart Failure Drugs Market Value (US$ Mn), by Right-sided Heart Failure, 2017-2031
  • Figure 09: Global Congestive Heart Failure Drugs Market Value (US$ Mn), by High-output Heart Failure, 2017-2031
  • Figure 10: Global Congestive Heart Failure Drugs Market Value Share Analysis, by Drug Class 2022 and 2031
  • Figure 11: Global Congestive Heart Failure Drugs Market Attractiveness Analysis, by Drug Class 2023-2031
  • Figure 12: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by ACE Inhibitors, 2017-2031
  • Figure 13: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by Angiotensin-2 Receptor Blockers (ARBs or AIIRAs), 2017-2031
  • Figure 14: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by Beta Blockers, 2017-2031
  • Figure 15: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by Mineralocorticoid Receptor Antagonists, 2017-2031
  • Figure 16: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by Diuretics, 2017-2031
  • Figure 17: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by Ivabradine, 2017-2031
  • Figure 18: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by Sacubitril Valsartan, 2017-2031
  • Figure 19: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by others (digoxin etc.), 2017-2031
  • Figure 20: Global Congestive Heart Failure Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 21: Global Congestive Heart Failure Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 22: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by Hospitals Pharmacies, 2017-2031
  • Figure 23: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by Retail Pharmacies, 2017-2031
  • Figure 24: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by Online Pharmacies, 2017-2031
  • Figure 25: Global Congestive Heart Failure Drugs Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 26: Global Congestive Heart Failure Drugs Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 27: North America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 28: North America Congestive Heart Failure Drugs Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 29: North America Congestive Heart Failure Drugs Market Attractiveness Analysis, by Country, 2023-2031 
  • Figure 30: North America Congestive Heart Failure Drugs Market Value Share Analysis, by Type of Congestive Heart Failure, 2022 and 2031
  • Figure 31: North America Congestive Heart Failure Drugs Market Attractiveness Analysis, by Type of Congestive Heart Failure, 2023-2031
  • Figure 32: North America Congestive Heart Failure Drugs Market Value Share Analysis, by Drug Class 2022 and 2031
  • Figure 33: North America Congestive Heart Failure Drugs Market Attractiveness Analysis, by Drug Class 2023-2031
  • Figure 34: North America Congestive Heart Failure Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 35: North America Congestive Heart Failure Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 36: Europe Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 37: Europe Congestive Heart Failure Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 38: Europe Congestive Heart Failure Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 39: Europe Congestive Heart Failure Drugs Market Value Share Analysis, by Type of Congestive Heart Failure, 2022 and 2031
  • Figure 40: Europe Congestive Heart Failure Drugs Market Attractiveness Analysis, by Type of Congestive Heart Failure, 2023-2031
  • Figure 41: Europe Congestive Heart Failure Drugs Market Value Share Analysis, by Drug Class 2022 and 2031
  • Figure 42: Europe Congestive Heart Failure Drugs Market Attractiveness Analysis, by Drug Class 2023-2031
  • Figure 43: Europe Congestive Heart Failure Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 44: Europe Congestive Heart Failure Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 45: Asia Pacific Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 46: Asia Pacific Congestive Heart Failure Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 47: Asia Pacific Congestive Heart Failure Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 48: Asia Pacific Congestive Heart Failure Drugs Market Value Share Analysis, by Type of Congestive Heart Failure, 2022 and 2031
  • Figure 49: Asia Pacific Congestive Heart Failure Drugs Market Attractiveness Analysis, by Type of Congestive Heart Failure, 2023-2031
  • Figure 50: Asia Pacific Congestive Heart Failure Drugs Market Value Share Analysis, by Drug Class 2022 and 2031
  • Figure 51: Asia Pacific Congestive Heart Failure Drugs Market Attractiveness Analysis, by Drug Class 2023-2031
  • Figure 52: Asia Pacific Congestive Heart Failure Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 53: Asia Pacific Congestive Heart Failure Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 54: Latin America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 55: Latin America Congestive Heart Failure Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 56: Latin America Congestive Heart Failure Drugs Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 57: Latin America Congestive Heart Failure Drugs Market Value Share Analysis, by Type of Congestive Heart Failure, 2022 and 2031
  • Figure 58: Latin America Congestive Heart Failure Drugs Market Attractiveness Analysis, by Type of Congestive Heart Failure, 2023-2031
  • Figure 59: Latin America Congestive Heart Failure Drugs Market Value Share Analysis, by Drug Class 2022 and 2031
  • Figure 60: Latin America Congestive Heart Failure Drugs Market Attractiveness Analysis, by Drug Class 2023-2031
  • Figure 61: Latin America Congestive Heart Failure Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 62: Latin America Congestive Heart Failure Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 63: Middle East & Africa Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 64: Middle East & Africa Congestive Heart Failure Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 65: Middle East & Africa Congestive Heart Failure Drugs Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 66: Middle East & Africa Congestive Heart Failure Drugs Market Value Share Analysis, by Type of Congestive Heart Failure, 2022 and 2031
  • Figure 67: Middle East & Africa Congestive Heart Failure Drugs Market Attractiveness Analysis, by Type of Congestive Heart Failure, 2023-2031
  • Figure 68: Middle East & Africa Congestive Heart Failure Drugs Market Value Share Analysis, by Drug Class 2022 and 2031
  • Figure 69: Middle East & Africa Congestive Heart Failure Drugs Market Attractiveness Analysis, by Drug Class 2023-2031
  • Figure 70: Middle East & Africa Congestive Heart Failure Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 71: Middle East & Africa Congestive Heart Failure Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 72: Company Share Analysis, 2022